^BOSTON, Dec. November 30, 2023 (GLOBE NEWSWIRE) — Novotech, (https://novotech-
cro.com/reports/gall-bladder-cancer-global-clinical-trial-
landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT
&utm_term=DOWNLOAD-REPORT&utm_content=GBC) the leading Asian-
Pacific-focused biotech CRO with global
Implementing Capacities, today released the latest report on the global
2023 clinical trial landscape published on HIV, a disease
which now affects more than 39 million people.
Novotech’s team of research analysts provides these expert reports on a monthly basis
available completely free of charge. These reports provide up-to-date insights into the
global activity of clinical trials and show in which regions the
highest study volumes have been recorded and what factors are behind them
Trends stand. They address the hurdles that biotech companies face
are confronted with certain therapeutic areas and discuss future ones
Therapy paths and investment trends.
According to the HIV Global Clinical Trial Landscape Report, the biopharmaceutical industry
Since 2018, over 1,000 clinical HIV studies have been initiated worldwide. The distribution
of the studies is as follows: Asia Pacific accounts for 29% of the
Studies, followed by Europe with 28% and North America with 26%, while the rest
in the world (ROW) accounts for a moderate share of 17%.
In Asia Pacific, mainland China had the highest at 45%
Study share. Within Europe, Spain, France, recorded this
United Kingdom, Italy and Germany have the most HIV studies. Under
Among the ROW countries, South Africa leads the way with 31% of HIV studies.
The report also reviewed caseload and mortality data for 2022
Regions.
* South Africa had 7.6 million cases and 45,000 AIDS-related deaths,
which highlights the serious impact within the country.
* India reported 2.5 million cases and 40,000 deaths, a
reflects a significant HIV burden.
* There were 1.2 million HIV cases in the United States, resulting in 19,986
led to deaths.
* Thailand reported 560,000 cases and 11,000 deaths.
* In Western Europe, France has had 200,000 cases and 880 deaths.
* Spain reported 150,000 cases and 640 deaths.
* Italy has had 140,000 cases and 550 deaths.
* Malaysia reported 86,000 cases and 2,500 deaths.
* New Zealand had comparatively 3,600 cases and 100 deaths
lower numbers.
The report analyzed global study risk and found that in the region
Asia Pacific with their large population and comparatively smaller ones
Study quantity the risk of competing studies is lower. The density of studies
in this region is more than six times lower than in the USA and about three times
lower than in Europe.
A review of HIV investment data between 2019 and 2022 found:?China
experienced a significant influx of venture capital with investments amounting to
totaling $1,534.8 million, while the United States spent $540.5 million
dollars to fight HIV. These investments mean
a global commitment to revolutionizing HIV prevention and treatment
and awareness-raising strategies.”
The report also examined developments in treatment and found
that advances in?HIV treatment come from innovative
Drug formulations through to therapeutic vaccines and genetic
Editing technologies range, reflecting ongoing efforts, uncovered
Meeting needs and making people living with HIV more accessible and effective
to provide options. The treatment paradigm changes with it
injectable options such as Cabenuva and Lenacapavir and offers alternatives for
the daily pill routine.”
“A weekly dose of islatravir and the experimental CRISPR
based gene editing method show the potential to alleviate HIV
treatment burden and provide long-lasting cures,” the report said.
An examination of the therapeutic pipeline as part of the report found
that it?across the spectrum of HIV drug development by phase one
promising progression with 50 drugs in preclinical phases
There are 61 in phase I studies and 15 in combined phase I/II studies.
Additionally, 34 drugs are in Phase II, 13 are in Phase III, with 9
approved and 61 drugs already on the market, which is one
“reflects a robust HIV treatment landscape.”
Download the report here (https://novotech-cro.com/reports/hiv-
global clinical trial
landscape?utm_source=PR+HIV&utm_medium=PR+HIV&utm_campaign=PR+HIV)
Novotech employs more than 3,000 people in 25 countries
34 branches, including in the USA, Greater China, South Korea,
Australia, New Zealand and Europe.
The CRO offers biotechnology companies a unique and unparalleled experience
Offering early to late phase contract research services
the USA and Europe, with a focus on the Asia-Pacific region
is where the company has a good reputation in terms of implementation
high-quality accelerated clinical trials.
Novotech has been recognized with numerous awards for its industry-leading contributions
Awards honored including the 2023 CRO Leadership Award and
the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence Award for
2022 and 2023. The company has also been awarded the Asian Award every year since 2006.
Pacific Contract Research Organization Company of the Year Award.
The company’s commitment to collaboration is evident in the
50 Leading Site Partnership agreements signed in the last three years
has signed.
Contact person for media
David James
[email protected] (mailto:[email protected])
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
About Novotech Novotech-CRO.com (https://novotech-cro.com/reports/gall-bladder-
cancer-global-clinical-trial-
landscape?utm_source=PRESS+RELEASE&utm_medium=PR&utm_campaign=GBC+DISEASE+REPORT
&utm_term=DOWNLOAD REPORT&utm_content=GBC)
Founded in 1997, Novotech is a global clinical
Full-service contract research organization (CRO) focused on
Collaboration with biotech companies focused on development
of advanced and novel therapeutics at every stage.
Recognized for its industry-leading contributions, Novotech has numerous
Received prestigious awards including the CRO Leadership Award
2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023 and
since 2006 the Asia-Pacific Contract Research Organization Company of the Year
Award.
The company offers a full range of services including
Laboratories, Phase I facilities, drug development consulting and
regulatory expertise, and has experience with over 5,000 clinical
Projects, including phase I to IV clinical trials and
Bioequivalence studies. With a presence in 34 locations and a dedicated
With a team of more than 3,000 professionals worldwide, Novotech is a trusted one
strategic end-to-end partner of choice.
For more information or to speak to an expert team member,
visit www.Novotech-CRO.com (http://www.novotech-cro.com/)
A photo accompanying this announcement is available
at https://www.globenewswire.com/NewsRoom/AttachmentNg/440766ee-b4d9-4f23-
a450-5efeb980cc1e
°